Latest Posts:

Sorry, no posts matched your criteria.

Follow Us:

Back To Top

JOIN OUR EFFORTS TO

Enable full identification, full clearance

by launching a science company.

Relying on surface, or even internal markers will always be a flawed strategy because they are never universal, constantly changing, and are often completely hidden during intermediate states, creating an advantage for the genetic profile not caught by the initial therapeutic dose.

One approach that has fallen in and out of favour over the years, is to use viruses which can selectively infect cancerous cells due to specific specific genetic or metabolic phenotypes, such as unregulated replication. This can then be used to lyse cancer cells, display a marker to the immune system, produce cytokines or prodrug convertase. The problem with this approach is that the virus are highly unlikely to make it into all of the cancerous cells because it is quickly spotted by the immune system and destroyed. Either pre-existing or adaptive immunity presents a problem, the immune system can destroy the virus quicker than it can destroy the tumour. The result is again being impressive initial results followed later by what is often even more aggressive recurrence.

Our starting point to explore this space is to ask how we can create a more effective balance between, on the one hand, evading the immune system and on the other hand, getting into every cancerous cell whilst pervading the tumour microenvironment. Next, once we have achieved this selective penetration, how do we drive a therapeutic regime that does not allow resistance to emerge? You can find out more about the skill-sets that we are bringing together to take on this challenge, here.

our offer

You will join our in-house team of entrepreneurial scientists as a ‘Founding Analyst’ to lead opportunity analysis and venture creation in this particular area. Specifically, you will focus on mapping out the constraints and limitations currently leading to a lack of innovation, and team building.

Our partnership with Cancer Research UK means that your work will also be supported by the world’s largest independent funder of cancer research. Further information about the DSV-CRUK programme here.

After six to nine months, it’s anticipated that you will co-found up to three start-ups in this space, taking the role of CEO or CTO at one. Each company will be created with £50,000 to cover initial proof of principle work. DSV may follow on up to £500,000 and Cancer Research UK is launching several seed, grant and later stage funding initiatives that may be relevant on a case by case basis.

Relying on surface, or even internal markers will always be a flawed strategy because they are never universal, constantly changing, and are often completely hidden during intermediate states, creating an advantage for the genetic profile not caught by the initial therapeutic dose.

One approach that has fallen in and out of favour over the years, is to use viruses which can selectively infect cancerous cells due to specific specific genetic or metabolic phenotypes, such as unregulated replication. This can then be used to lyse cancer cells, display a marker to the immune system, produce cytokines or prodrug convertase. The problem with this approach is that the virus are highly unlikely to make it into all of the cancerous cells because it is quickly spotted by the immune system and destroyed. Either pre-existing or adaptive immunity presents a problem, the immune system can destroy the virus quicker than it can destroy the tumour. The result is again being impressive initial results followed later by what is often even more aggressive recurrence.

Our starting point to explore this space is to ask how we can create a more effective balance between, on the one hand, evading the immune system and on the other hand, getting into every cancerous cell whilst pervading the tumour microenvironment. Next, once we have achieved this selective penetration, how do we drive a therapeutic regime that does not allow resistance to emerge? You can find out more about the skill-sets that we are bringing together to take on this challenge, here.

our offer
You will join our in-house team of entrepreneurial scientists as a ‘Founding Analyst’ to lead opportunity analysis and venture creation in this particular area. Specifically, you will focus on mapping out the constraints and limitations currently leading to a lack of innovation, and team building.
Our partnership with Cancer Research UK means that your work will also be supported by the world’s largest independent funder of cancer research. Further information about the DSV-CRUK programme here.
After six to nine months, it’s anticipated that you will co-found up to three start-ups in this space, taking the role of CEO or CTO at one. Each company will be created with £50,000 to cover initial proof of principle work. DSV may follow on up to £500,000 and Cancer Research UK is launching several seed, grant and later stage funding initiatives that may be relevant on a case by case basis.
the ideal profile for this opportunity will have experience in a mix of the following areas:
the ideal profile for this opportunity will have experience in a mix of the following areas:

Either someone coming from the onco-lytic (or non-lytic) virus angle but focused on how to make them less immuno-genic, perhaps with experience in Vaccinia, Herpes, T-vec, adenovirus, rheovirus, parvovirus, etc. at one of the key companies in the space. Or with experience in modification of the viral envelope or capsids or design of synthetic alternatives such as nanoparticle and associated immune evasion / stealth strategies such as CD47 and the broader biocorona interactions. The second area required is likely around the in-cell genetic analysis required to understand and respond differentially to the state of the cell, assess genetic and epigenetic stability, DNA methylation patterns and translational states and methylation dependent transcription factors. We don’t expect any FA to have deep expertise in both but deep in one and light in the other or medium in both (with deep expertise in another relevant biochem / genetic / chemistry area) would be an advantage. 

Either someone coming from the onco-lytic (or non-lytic) virus angle but focused on how to make them less immuno-genic, perhaps with experience in Vaccinia, Herpes, T-vec, adenovirus, rheovirus, parvovirus, etc. at one of the key companies in the space. Or with experience in modification of the viral envelope or capsids or design of synthetic alternatives such as nanoparticle and associated immune evasion / stealth strategies such as CD47 and the broader biocorona interactions. The second area required is likely around the in-cell genetic analysis required to understand and respond differentially to the state of the cell, assess genetic and epigenetic stability, DNA methylation patterns and translational states and methylation dependent transcription factors. We don’t expect any FA to have deep expertise in both but deep in one and light in the other or medium in both (with deep expertise in another relevant biochem / genetic / chemistry area) would be an advantage. 

Applications close November 30th!

Interviews start from 18th of October with places allocated as soon as the right fit is found.

Applications close November 30th!

Interviews start from 18th of October with places allocated as soon as the right fit is found.